Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Mallinckrodt PLC    MNK   IE00BBGT3753

MALLINCKRODT PLC (MNK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Mallinckrodt : To Present At Deutsche Bank's 43rd Annual Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2018 | 05:46am EDT

STAINES-UPON-THAMES - Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Wednesday, May 9, 2018, at Deutsche Bank's 43rd Annual Healthcare Conference at the Intercontinental Hotel Boston, 510 Atlantic Ave., in Boston.

Mark Trudeau, President and Chief Executive Officer, and Dr. Steven Romano, Executive Vice President and Chief Scientific Officer, will represent the company in a fireside chat at 12:50 p.m. Eastern.

ABOUT MALLINCKRODT

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Contact:

Daniel J. Speciale

Tel: 314-654-3638

Email: [email protected]

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
DEUTSCHE BANK -0.96% 11.574 Delayed Quote.-27.09%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MALLINCKRODT PLC
04/20MALLINCKRODT : To Present At UBS Global Healthcare Conference
PR
04/20MALLINCKRODT : Announces $300 Million Debt Repayment
AQ
04/16MALLINCKRODT PLC : Announces $300 Million Debt Repayment
PR
04/12MALLINCKRODT : Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of..
AQ
04/12MALLINCKRODT : To Present At Deutsche Bank's 43rd Annual Healthcare Conference
AQ
04/09MALLINCKRODT : To Present At Deutsche Bank's 43rd Annual Healthcare Conference
PR
04/06MALLINCKRODT : Names Paul R. Carter, Anne C. Whitaker to its Board of Directors
AQ
04/06MALLINCKRODT : Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of..
AQ
04/04MALLINCKRODT : Names Paul R. Carter, Anne C. Whitaker to its Board of Directors
PR
04/04MALLINCKRODT : Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of..
PR
More news
News from SeekingAlpha
04/21MALLINCKRODT : Are Bondholders Predicting Impending Doom? 
04/20Vilas Fund, LP Q1 '18 Letter To Partners - #28 Since Inception, Long Pharma 
04/19Novartis Q1 results weigh on pharma stocks 
04/19INSTITUTIONAL TOP IDEAS SERIES : Scopia Capital 
04/19U.S. opioid prescriptions down 12% last year, largest drop in 25 years 
Financials ($)
Sales 2018 2 463 M
EBIT 2018 948 M
Net income 2018 376 M
Debt 2018 5 250 M
Yield 2018 -
P/E ratio 2018 27,13
P/E ratio 2019 5,01
EV / Sales 2018 2,61x
EV / Sales 2019 2,13x
Capitalization 1 189 M
Chart MALLINCKRODT PLC
Duration : Period :
Mallinckrodt PLC Technical Analysis Chart | MNK | IE00BBGT3753 | 4-Traders
Technical analysis trends MALLINCKRODT PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 25,0 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
Mark C. Trudeau President, Chief Executive Officer & Director
Melvin D. Booth Chairman
Frank Scholz Executive Vice President-Global Operations
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Steven Romano Chief Scientific Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
MALLINCKRODT PLC-39.01%1 189
ABBVIE-4.25%146 927
MERCK KGAA-8.61%13 024
KYOWA HAKKO KIRIN CO LTD6.80%12 707
JAZZ PHARMACEUTICALS PLC17.30%9 446
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD35.57%8 212